Ajay Tambralli1, Timothy Beukelman1, Randy Quentin Cron1, Matthew Laurence Stoll2. 1. From the University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology, Birmingham, Alabama; University of Rochester Medical Center, Department of Medicine, Rochester, New York, USA.A. Tambralli, MD, University of Rochester Medical Center, Department of Medicine; T. Beukelman, MD, MSCE; R.Q. Cron, MD, PhD; M.L. Stoll, MD, PhD, MSCS, University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology. 2. From the University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology, Birmingham, Alabama; University of Rochester Medical Center, Department of Medicine, Rochester, New York, USA.A. Tambralli, MD, University of Rochester Medical Center, Department of Medicine; T. Beukelman, MD, MSCE; R.Q. Cron, MD, PhD; M.L. Stoll, MD, PhD, MSCS, University of Alabama at Birmingham, Department of Pediatrics, Division of Rheumatology. mstoll@peds.uab.edu.
Abstract
OBJECTIVE: Rituximab (RTX) has been used to treat many pediatric autoimmune conditions. We investigated the safety and efficacy of RTX in a variety of pediatric autoimmune diseases, especially systemic lupus erythematosus (SLE). METHODS: Retrospective study of children treated with RTX. Effectiveness data was recorded for patients with at least 12 months of followup; safety data was recorded for all subjects. RESULTS: The study included 104 children; 50 had SLE. Improvements in corticosteroid dosage, physician's global assessment of disease activity, and SLE-associated markers of disease activity were seen. The incidence of hospitalized infections was similar to previous studies of patients with childhood-onset SLE. CONCLUSION: RTX can be safely administered to children and appears to contribute to decreased disease activity and steroid burden.
OBJECTIVE:Rituximab (RTX) has been used to treat many pediatric autoimmune conditions. We investigated the safety and efficacy of RTX in a variety of pediatric autoimmune diseases, especially systemic lupus erythematosus (SLE). METHODS: Retrospective study of children treated with RTX. Effectiveness data was recorded for patients with at least 12 months of followup; safety data was recorded for all subjects. RESULTS: The study included 104 children; 50 had SLE. Improvements in corticosteroid dosage, physician's global assessment of disease activity, and SLE-associated markers of disease activity were seen. The incidence of hospitalized infections was similar to previous studies of patients with childhood-onset SLE. CONCLUSION:RTX can be safely administered to children and appears to contribute to decreased disease activity and steroid burden.
Authors: Courtney B Crayne; Esraa Eloseily; Melissa L Mannion; Saji P Azerf; Peter Weiser; Timothy Beukelman; Matthew L Stoll; Daniel I Feig; T Prescott Atkinson; Randy Quentin Cron Journal: Pediatr Rheumatol Online J Date: 2018-11-14 Impact factor: 3.054
Authors: Casey Lee McAtee; Joseph Lubega; Kristen Underbrink; Kristen Curry; Pavlos Msaouel; Martha Barrow; Eyal Muscal; Timothy Lotze; Poyyapakkam Srivaths; Lisa R Forbes; Carl Allen; M Brooke Bernhardt Journal: JAMA Netw Open Date: 2021-02-01
Authors: Chengappa Kavadichanda; M B Adarsh; Sajal Ajmani; Ilaria Maccora; S Balan; A V Ramanan; Vikas Agarwal; Latika Gupta Journal: Mediterr J Rheumatol Date: 2021-12-27